Skip to main content

Clinical Data and Duke University to Collaborate on Statin PGx Research

NEW YORK, May 12 (GenomeWeb News) - Clinical Data announced today that it has entered into a five-year research collaboration agreement with the Institute for Genome Sciences & Policy at Duke University to discover genetic variants associated with baseline lipid parameters and the response of these parameters to statins.


Under terms of the agreement, Clinical Data's PGxHealth division will non-exclusively provide Duke with confidential access to its Strength studies, which involved evaluating the response of 679 patients to atorvastatin, pravastatin, simvastatin, lovastatin, and cerivastatin; genotopying approximately 175 genes; and evaluating 700 control patients at baseline. In return, Clinical Data will have the right to evaluate the commercial potential of any findings derived from Duke studies which used Strength clinical and/or genetic databases.


Duke researchers are planning a series to studies to find and validate associations between genetic variants and responses to drugs used for dyslipidemia, or hypercholesterolemia, Clinical Data said. The university is also planning on carrying out similar studies in the areas of hypertension and asthma.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.